CODX Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.10 |
52 Week High | US$1.89 |
52 Week Low | US$0.97 |
Beta | -0.66 |
1 Month Change | -4.35% |
3 Month Change | -0.90% |
1 Year Change | -16.67% |
3 Year Change | -86.06% |
5 Year Change | 34.64% |
Change since IPO | -81.07% |
Recent News & Updates
Recent updates
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
May 18A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Apr 14Co-Diagnostics: Hold Thesis Remains Well Intact
Sep 07Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes
Aug 11Co-Diagnostics spikes on shipments of monkeypox test
Jul 11Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Jul 06Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant
Jun 21Co-Diagnostics: Where's Eikon?
Apr 03Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 28Co-Diagnostics: Swinging For The Fences
Jan 24Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?
Dec 28Why Co-Diagnostics Is A Solid Covid-19 Play
Aug 19Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Aug 14Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test
Jun 18Co-Diagnostics: No One-Hit Wonder
Jun 04This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year
May 18Shareholder Returns
CODX | US Medical Equipment | US Market | |
---|---|---|---|
7D | -1.8% | 1.1% | 1.2% |
1Y | -16.7% | 4.2% | 27.7% |
Return vs Industry: CODX underperformed the US Medical Equipment industry which returned 1% over the past year.
Return vs Market: CODX underperformed the US Market which returned 26% over the past year.
Price Volatility
CODX volatility | |
---|---|
CODX Average Weekly Movement | 6.9% |
Medical Equipment Industry Average Movement | 8.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CODX has not had significant price volatility in the past 3 months.
Volatility Over Time: CODX's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 155 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
CODX fundamental statistics | |
---|---|
Market cap | US$34.39m |
Earnings (TTM) | -US$38.89m |
Revenue (TTM) | US$6.68m |
5.1x
P/S Ratio-0.9x
P/E RatioIs CODX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CODX income statement (TTM) | |
---|---|
Revenue | US$6.68m |
Cost of Revenue | US$3.92m |
Gross Profit | US$2.76m |
Other Expenses | US$41.65m |
Earnings | -US$38.89m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.24 |
Gross Margin | 41.34% |
Net Profit Margin | -582.36% |
Debt/Equity Ratio | 0% |
How did CODX perform over the long term?
See historical performance and comparison